United Therapeutics Corporation $UTHR Shares Purchased by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd boosted its position in United Therapeutics Corporation (NASDAQ:UTHR) by 29.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,062 shares of the biotechnology company’s stock after acquiring an additional 1,146 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in United Therapeutics were worth $2,466,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Torren Management LLC acquired a new stake in United Therapeutics in the fourth quarter valued at approximately $26,000. Activest Wealth Management raised its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares in the last quarter. Wilmington Savings Fund Society FSB raised its holdings in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares in the last quarter. Harbor Capital Advisors Inc. acquired a new stake in United Therapeutics during the fourth quarter worth approximately $48,000. Finally, Abich Financial Wealth Management LLC acquired a new stake in United Therapeutics during the third quarter worth approximately $44,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on UTHR shares. Raymond James Financial started coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. TD Cowen raised their price objective on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Bank of America raised their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Finally, UBS Group raised their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $619.42.

Insiders Place Their Bets

In related news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction on Monday, February 9th. The shares were sold at an average price of $474.65, for a total value of $10,679,625.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $9,956,712.48. This trade represents a 34.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 485,155 shares of company stock worth $266,370,949. 10.30% of the stock is currently owned by insiders.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Investors are focusing on United Therapeutics’ pipeline and growth catalysts, especially encouraging Tyvaso data in IPF and optimism around ralinepag’s blockbuster potential, which could support future revenue growth. UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook
• Positive Sentiment: Royal Bank of Canada kept an outperform rating and only slightly lowered its price target to $701 from $707, signaling continued confidence in upside from current levels. RBC lowers price target on UTHR
• Neutral Sentiment: United Therapeutics held its Q1 2026 earnings call, which investors are likely parsing for commentary on Tyvaso, ralinepag, and the company’s growth outlook. Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q1 results missed estimates, with EPS of $5.82 versus expectations of $7.00 and revenue of $781.5 million versus $797.4 million expected; revenue also declined 1.6% year over year. Q1 2026 Financial Results
• Negative Sentiment: Insider selling may be weighing on sentiment: CEO Martine Rothblatt sold 9,500 shares and EVP Paul Mahon sold 8,300 shares, both sizable reductions in their holdings. Rothblatt SEC filing Mahon SEC filing

United Therapeutics Price Performance

NASDAQ:UTHR opened at $564.94 on Friday. The firm’s fifty day moving average price is $550.17 and its 200 day moving average price is $501.37. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The firm has a market cap of $23.98 billion, a price-to-earnings ratio of 20.85, a price-to-earnings-growth ratio of 1.77 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter last year, the business earned $6.63 earnings per share. The business’s quarterly revenue was down 1.6% on a year-over-year basis. As a group, analysts expect that United Therapeutics Corporation will post 27.4 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.